5-[1-(2-pyridyl)pyrazolo[3,4-b]pyridin-4-yl]pyrimidin-4-amine

ID: ALA5289901

Max Phase: Preclinical

Molecular Formula: C15H11N7

Molecular Weight: 289.30

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Nc1ncncc1-c1ccnc2c1cnn2-c1ccccn1

Standard InChI:  InChI=1S/C15H11N7/c16-14-11(7-17-9-20-14)10-4-6-19-15-12(10)8-21-22(15)13-3-1-2-5-18-13/h1-9H,(H2,16,17,20)

Standard InChI Key:  FOAUXFIKYAXLLY-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 22 25  0  0  0  0  0  0  0  0999 V2000
   -1.1434    1.0307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1450    0.2057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8602   -0.2053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4312   -0.2080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2839    0.2030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.2854    1.0280    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.4282    1.4419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9015   -0.3692    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.5695   -1.1031    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2543   -1.0092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6986   -0.1557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9124    0.6413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7074    0.8536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2910    0.2699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.0800   -0.5236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2846   -0.7417    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8617   -1.0306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5771   -1.4419    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2910   -1.0280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2896   -0.2027    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5741    0.2085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5741    1.0337    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  1  1  0
  5  8  1  0
  8  9  1  0
 10  9  2  0
  4 10  1  0
  8 11  1  0
 12 11  2  0
 13 12  1  0
 14 13  2  0
 15 14  1  0
 16 15  2  0
 11 16  1  0
 17  3  2  0
 18 17  1  0
 19 18  2  0
 20 19  1  0
 21 20  2  0
  3 21  1  0
 21 22  1  0
M  END

Alternative Forms

  1. Parent:

    ALA5289901

    ---

Associated Targets(Human)

CYP17A1 Tclin Cytochrome P450 17A1 (3627 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP1A2 Tchem Cytochrome P450 1A2 (26471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 289.30Molecular Weight (Monoisotopic): 289.1076AlogP: 1.85#Rotatable Bonds: 2
Polar Surface Area: 95.40Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 5.17CX LogP: 1.09CX LogD: 1.09
Aromatic Rings: 4Heavy Atoms: 22QED Weighted: 0.60Np Likeness Score: -1.62

References

1. Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A..  (2022)  The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.,  75  [PMID:36031020] [10.1016/j.bmcl.2022.128951]

Source